Theratechnologies (TSX:TH) is pleased to announce that the European Medicines Agency has confirmed the validity of the marketing authorization application for Trogarzo (ibalizumab) filed on August 28, 2018. The validation confirms the submission is complete, and begins the EMA’s centralized review process. As a result, the start of procedure date has been set to September … Continued
The post European Medicines Agency Validates Marketing Authorization Application for Trogarzo appeared first on Investing News Network.